IMNN Imunon, Inc.

CIK 0000749647 50 ready 8-Ks latest June 30, 2026, 4:30 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing June 30, 2026, 4:30 PM ET

Top materiality 0.85

Event mix other_material ×17 · earnings ×12 · leadership ×10

Sentiment 13 pos · 8 neg · 29 neu

Latest earnings ▲ beat 2026-Q1

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for IMNN

Highest-materiality recent filing

Imunon reports Q1 net loss $4.3M; Phase 2 ovarian data shows 14.7-month OS improvement

May 12, 2026, 8:05 AM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Net loss of $4.3M ($0.84 per share) vs $4.1M ($3.15 per share) in Q1 2025; cash $4.8M at March 31, 2026.
Phase 2 OVATION 2 final data: median OS 45.1 vs 30.4 months (+14.7 months) for IMNN-001+SoC vs SoC alone.

Read filing →

June 30, 2026, 4:30 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01

Imunon CFO Jeffrey Church to retire; Josh Blacher appointed interim CFO effective July 1, 2026

Jeffrey Church retires as interim CFO effective July 1, 2026; will continue as consultant at $10,000/month retainer.
June 16, 2026, 5:30 PM ET other material materiality 0.45 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

Imunon shareholders approve 1M share increase to 2018 Stock Incentive Plan at annual meeting

Stockholders approved amendment increasing shares available under 2018 Stock Incentive Plan by 1,000,000 to 1,265,004.
June 4, 2026, 8:00 AM ET debt materiality 0.70 neutral item 1.01 item 2.03 item 3.02 item 5.03 item 7.01 item 9.01 ◈ Debt Financings ×2◈ Governance Changes◈ Material Agreements

IMUNON secures up to $10M through preferred stock and secured notes for Phase 3 trial

Gross proceeds of $10M from 250 Series A Preferred shares ($2.5M) and secured promissory notes ($7.72M total).
May 12, 2026, 8:05 AM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases

Imunon reports Q1 net loss $4.3M; Phase 2 ovarian data shows 14.7-month OS improvement

Net loss of $4.3M ($0.84 per share) vs $4.1M ($3.15 per share) in Q1 2025; cash $4.8M at March 31, 2026.
May 4, 2026, 7:59 PM ET other material materiality 0.50 neutral item 5.02 item 9.01

Imunon enters change of control severance agreements with CEO, CMO, and GC

CEO Lindborg gets 2.5x base salary plus target bonus severance; others get 1.5x.
March 31, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Imunon FY2025 net loss $14.5M; Phase 2 OS benefit 14.7 months

Net loss for 2025 was $14.5M ($6.83/sh) vs $18.6M ($16.94/sh) in 2024; operating expenses down 23%.
March 23, 2026, 7:59 PM ET other material materiality 0.50 neutral item 8.01 item 9.01

Imunon registers additional $7M in common stock under existing ATM facility

Filed prospectus supplement to increase ATM capacity from $10M to $17M in common stock.
February 5, 2026, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01

CSO Khursheed Anwer retires effective Feb 20, 2026; transitions to consulting role

Khursheed Anwer will retire as EVP and Chief Scientific Officer on February 20, 2026.
January 7, 2026, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01

Imunon interim CFO Graper resigns; Church appointed as interim CFO effective Jan 14

Kimberly Graper resigns as interim CFO effective Jan 14, 2026; no disagreements with management.
December 31, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Imunon raises $7.0M in registered direct offering of common stock and warrants

Gross proceeds ~$7.0M from 1,939,114 shares/pre-funded warrants plus warrants at $3.61/unit.
November 13, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Imunon posts Q3 net loss of $3.4M, cash $5.3M; Phase 3 ovarian cancer study enrollment ahead

Net loss of $3.4M ($1.16/sh) in Q3 2025 vs $4.8M ($3.76/sh) in Q3 2024; operating expenses down 30% to $3.5M.
August 28, 2025, 7:59 PM ET other material materiality 0.60 positive item 3.01 item 9.01 ◈ Listing & Compliance Notices

Imunon regains Nasdaq minimum bid price compliance; trading continues uninterrupted

Received Nasdaq Hearings Panel confirmation of regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).
August 5, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Imunon Q2 net loss narrows to $2.7M, cash $4.7M; first patient dosed in Phase 3 ovarian cancer trial

Net loss $2.7M ($2.15/shr) vs $4.8M ($7.64/shr) YoY; operating expenses down 45% to $2.8M.
July 28, 2025, 7:59 PM ET dividend materiality 0.35 positive item 8.01 item 9.01

Imunon declares 15% stock dividend, payable Aug 21, 2025

Board approved 15% stock dividend: 0.15 shares per common share and equivalents.
July 23, 2025, 7:59 PM ET other materiality 0.60 negative item 3.03 item 5.03 item 7.01 item 8.01 item 9.01 ◈ Governance Changes

Imunon to effect 1-for-15 reverse stock split on July 25, 2025 to maintain Nasdaq listing

Reverse split at 1-for-15 ratio effective 12:01 a.m. ET on July 25, 2025.
July 22, 2025, 7:59 PM ET other material materiality 0.55 neutral item 8.01 item 9.01

Imunon upsizes ATM equity facility by $4.5M to $10M total capacity

Filed prospectus supplement registering an additional $4.5M of common stock under existing ATM Sales Agreement with H.C. Wainwright.
July 14, 2025, 7:59 PM ET other material materiality 0.70 negative item 3.01 item 5.02 ◈ Listing & Compliance Notices

Nasdaq panel grants Imunon listing compliance exception; equity plan expanded by 2M shares

Nasdaq Hearing Panel granted Imunon an exception to regain compliance with minimum bid price ($1.00) and stockholders' equity ($5M) requirements.
July 11, 2025, 7:59 PM ET other material materiality 0.65 neutral item 3.03 item 5.07 item 5.03 item 9.01 ◈ Governance Changes

Imunon shareholders approve increase in authorized shares to 350M and reverse split up to 1:18

Authorized common shares increased from 112.5M to 350M; amendment effective July 11, 2025.
June 13, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01 ◈ executive_change ×2

Imunon terminates interim CFO Gaiero, appoints Kimberly Graper as interim CFO effective June 13

Terminated consulting agreement with Monomoy Advisors and David Gaiero as interim CFO, effective June 13, 2025.
June 9, 2025, 7:59 PM ET regulatory materiality 0.55 neutral item 8.01

Imunon regains Nasdaq minimum bid price compliance; delisting hearing pending on equity deficiency

Closing bid price above $1.00 for 10 consecutive days as of June 6, 2025, meeting bid price requirement.
May 30, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices ×2

Imunon receives Nasdaq delisting notice for bid price and equity non-compliance

Delisting determination letter received May 28, 2025 for failure to regain $1.00 minimum bid price by May 27, 2025.
May 27, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 8.01 item 9.01

Imunon raises $3.25M upfront in private placement; warrants could add $6.5M

Private placement raises $3.25M upfront from common stock and pre-funded warrants.
May 22, 2025, 7:59 PM ET other material materiality 0.70 negative item 8.01

Imunon withdraws S-1 registration statement for proposed public offering

Company requested SEC consent to withdraw S-1 (File No. 333-286403) on May 22, 2025.
May 20, 2025, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

Imunon receives Nasdaq notice for failing to meet $2.5M stockholders' equity requirement

Nasdaq notified Imunon on May 19, 2025 of non-compliance with minimum stockholders' equity of $2.5M (Listing Rule 5550(b)(1)).
May 13, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 9.01

Imunon exchanges warrants for 2.921M shares, representing 19.98% of outstanding

Issued 2,921,000 shares to warrant holders in exchange for warrants exercisable for 5,000,000 shares.
May 12, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Imunon Q1 net loss $4.1M; cash only through late Q2 2025; Phase 3 ovarian cancer trial initiated

Net loss $4.1M ($0.28 per share) vs $4.9M ($0.52 per share) in Q1 2024; operating expenses down 18%.
March 24, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

IMUNON finalizes Phase 3 OVATION 3 trial design with FDA for IMNN-001 in advanced ovarian cancer

FDA aligns on Phase 3 protocol for IMNN-001 plus NACT vs NACT alone in newly diagnosed advanced ovarian cancer (stage 3/4).
February 27, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Imunon reports FY2024 net loss $18.6M, OS benefit 13mo for IMNN-001, Phase 3 start Q1 2025

Net loss $18.6M ($1.62/share) in 2024 vs $19.5M in 2023; cash $5.9M at year-end, sufficient into late Q2 2025.
February 10, 2025, 6:59 PM ET leadership materiality 0.60 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

Imunon appoints Dr. Douglas Faller as CMO; Phase 3 trial on track for Q1 2025

Dr. Douglas Faller appointed Chief Medical Officer effective Feb 18, 2025, to lead clinical strategy.
November 27, 2024, 6:59 PM ET regulatory materiality 0.65 negative item 3.01

Imunon receives Nasdaq bid price deficiency notice; 180 days to regain compliance

Bid price closed below $1.00 for 30 consecutive business days as of Nov 26, 2024.
November 7, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Imunon Q3 net loss $4.9M; progressing toward Phase 3 for IMNN-001 in ovarian cancer

Net loss of $4.9M ($0.34 per share) vs $3.5M in Q3 2023; R&D expense $3.3M, G&A $1.7M.
October 7, 2024, 7:59 PM ET leadership materiality 0.35 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Imunon appoints Susan Eylward as General Counsel and Corporate Secretary; grants inducement stock options

Susan Eylward appointed General Counsel and Corporate Secretary effective October 7, 2024.
September 3, 2024, 7:59 PM ET other material materiality 0.20 neutral item 8.01 item 9.01

Imunon resumes at-the-market stock offering after previous suspension

On Sept 3, 2024, Imunon filed a new prospectus supplement to resume sales under the existing ATM agreement.
August 14, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Imunon reports positive Phase 2 OS data for IMNN-001; net loss narrows in Q2 2024

Q2 net loss of $4.8M ($0.51/share) vs $5.6M ($0.61/share) in Q2 2023; operating expenses down 8%.
August 1, 2024, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Imunon files prospectus supplement for 5M share registered direct offering

Registered direct offering of 5,000,000 shares of common stock (par value $0.01).
July 31, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 3.02 item 8.01 item 9.01

IMUNON announces $10M registered direct offering of 5M shares and warrants at $2.00, closing Aug 1

Selling 5,000,000 common shares and warrants to purchase 5,000,000 shares at $2.00 per unit.
July 30, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Imunon reports Phase 2 OVATION 2 trial: 11.1-month OS increase in advanced ovarian cancer with IMNN-001

Median OS improved by 11.1 months (40.5 vs 29.4) in ITT; HR 0.74 (0.42-1.30).
June 13, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07 item 9.01

Imunon 2024 annual meeting: directors elected, auditor ratified, say-on-pay approved

Dr. Stacy R. Lindborg and James E. Dentzer elected as directors with 1.63M and 1.56M votes for.
May 20, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change ×2

CFO Jeffrey Church retiring June 1; David Gaiero appointed as successor

Jeffrey Church to retire as CFO effective June 1, 2024; will serve as consultant through Dec 31, 2024.
May 13, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Imunon Q1 net loss $4.9M ($0.52/shr), appoints Stacy Lindborg as CEO; OVATION 2 data expected mid-2024

Net loss of $4.9M ($0.52/shr) vs $5.6M ($0.68/shr) in Q1 2023; operating expenses down 12% to $5.0M.
May 8, 2024, 7:59 PM ET leadership materiality 0.70 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

Imunon appoints Dr. Stacy R. Lindborg as President and CEO effective May 13

Employment agreement: $567,000 base salary, 100% target bonus, 225,000 stock options vesting over 4 years, $200,000 sign-on bonus.
April 11, 2024, 7:59 PM ET regulatory materiality 0.60 positive item 8.01 item 9.01

Imunon regains Nasdaq minimum bid price compliance, deficiency resolved

Nasdaq notified Imunon on April 10, 2024, that compliance with Listing Rule 5550(a)(2) was regained after 10 consecutive trading days with bid price over $1.00.
March 28, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Imunon reports 2023 net loss $19.5M; OVATION 2 shows ~30% PFS delay, ~9 months OS improvement

Net loss $19.5M ($2.16 per share) vs $35.9M ($5.03 per share) in 2022; operating expenses down 17%.
March 18, 2024, 7:59 PM ET other materiality 0.20 neutral item 5.03 item 9.01 ◈ Governance Changes

Imunon amends bylaws to revise voting thresholds and adjournment procedures per DGCL changes

Board approved amendments effective March 15, 2024; Amended and Restated Bylaws filed as Exhibit 3.1.
March 12, 2024, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Imunon CEO Corinne Le Goff resigns; Executive Chairman Tardugno assumes interim leadership

Dr. Corinne Le Goff resigned as President, CEO, and Board member, effective March 15, 2024, to pursue another opportunity.
December 29, 2023, 6:59 PM ET other material materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

Imunon receives Nasdaq deficiency notice for bid price below $1.00 per share

Received Nasdaq deficiency letter on Dec. 26, 2023; bid price closed below $1.00 for 30 consecutive business days.
December 11, 2023, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Imunon appoints Dr. Sébastien Hazard as EVP and Chief Medical Officer

Dr. Hazard joins as EVP and CMO effective Dec. 11, 2023; previously Head of Clinical Development at Bicycle Therapeutics.
November 14, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Imunon Q3 net loss $3.5M; OVATION 2 shows 33% PFS improvement, OS benefit

Net loss of $3.5M ($0.37 per share) vs $6.1M loss in Q3 2022; operating expenses down 38% to $3.9M.
August 10, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Imunon Q2 net loss narrows to $5.6M; cash $24.1M; on track for COVID IND Q1 2024

Net loss Q2 2023 $5.6M ($0.61/sh) vs $6.0M ($0.87/sh) in Q2 2022; operating expenses down 10% YoY.
June 15, 2023, 7:59 PM ET other materiality 0.30 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×5

IMUNON stockholders approve 2018 Stock Incentive Plan amendment, increasing authorized shares to 1,970,000

Stockholders approved amendment to 2018 Stock Incentive Plan, increasing shares available from 940,000 to 1,970,000.

Executive changes

Departed (interim)

David Gaiero

interim Chief Financial Officer

IMNN · Imunon, Inc.

Effective: 2025-06-13
Successor: Kimberly Graper
Filed: June 13, 2025, 7:59 PM ET

On June 13, 2025, Imunon, Inc. (the “Company”) terminated the consulting agreement (as amended, the “Agreement”), dated April 15, 2024, by and between the Company and Monomoy Advisors, LLC, a financial advisory services firm (“Monomoy”), as well as David Gaiero’s service pursuant to the Agreement as the Company’s interim Chief Financial Officer (a position he has held since June of 2024), in each case effective June 13, 2025.

Appointed (interim)

Kimberly Graper

interim Chief Financial Officer

IMNN · Imunon, Inc.

Effective: 2025-06-13
Filed: June 13, 2025, 7:59 PM ET

As a result of the termination of the Agreement and Mr. Gaiero’s related service, effective June 13, 2025, the Company appointed Kimberly Graper to serve as the Company’s interim Chief Financial Officer.

Appointed

Douglas Faller

Chief Medical Officer

IMNN · Imunon, Inc.

Effective: 2025-02-18
Filed: February 10, 2025, 6:59 PM ET

On February 9, 2025, the Board of Directors of Imunon, Inc. (the “Company”) appointed Dr. Douglas Faller (age 72) as Chief Medical Officer.

Appointed

Susan Eylward

General Counsel and Corporate Secretary

IMNN · Imunon, Inc.

Effective: 2024-10-07
Filed: October 7, 2024, 7:59 PM ET

On October 4, 2024, the Board of Directors of Imunon, Inc. (the “Company”) appointed Susan Eylward (age 45) as General Counsel and Corporate Secretary.

Departed

Jeffrey Church

Chief Financial Officer

IMNN · Imunon, Inc.

Effective: 2024-06-01
Successor: David Gaiero
Filed: May 20, 2024, 7:59 PM ET

On May 15, 2024, Jeffrey Church informed Imunon, Inc. (the “Company”) of his intent to retire from all positions with the Company

Appointed

David Gaiero

Chief Financial Officer

IMNN · Imunon, Inc.

Effective: 2024-06-01
Filed: May 20, 2024, 7:59 PM ET

effective June 1, 2024, the Company appointed David Gaiero to serve as the Company’s new Chief Financial Officer

Appointed

Stacy R. Lindborg

President and Chief Executive Officer

IMNN · Imunon, Inc.

Effective: 2024-05-13
Filed: May 8, 2024, 7:59 PM ET

On May 8, 2024, Imunon, Inc. (the “Company”) announced the appointment of Stacy R. Lindborg, Ph.D., as President and Chief Executive Officer of the Company, effective as of May 13, 2024.

Departed

Corinne Le Goff

President and Chief Executive Officer

IMNN · Imunon, Inc.

Effective: 2024-03-15
Filed: March 12, 2024, 7:59 PM ET

On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors (the “Board”) of Imunon, Inc. (the “Company”) of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024.

Appointed

Dr. Sébastien Hazard

Executive Vice President and Chief Medical Officer

IMNN · Imunon, Inc.

Effective: 2023-12-11
Filed: December 11, 2023, 6:59 PM ET

On December 7, 2023, Imunon, Inc. (the “Company”) appointed Dr. Sébastien Hazard to the positions of Executive Vice President and Chief Medical Officer of the Company, effective as of December 11, 2023.

Departed

Augustine Chow

Class I Director

IMNN · Imunon, Inc.

Effective: 2023-06-14
Filed: June 14, 2023, 7:59 PM ET

On June 14, 2023, Augustine Chow, Ph.D., a Class I member of the Board of Directors (the “Board”) of Imunon, Inc. (the “Registrant”), retired from the Registrant’s Board upon conclusion of the 2023 Annual Meeting of Stockholders (the “Meeting”).

Departed

Nicholas Borys

Executive Vice President and Chief Medical Officer

IMNN · Imunon, Inc.

Effective: 2023-02-28
Filed: February 10, 2023, 6:59 PM ET

On February 10, 2023, Imunon, Inc., a Delaware corporation (“Imunon”), announced that Nicholas Borys, its Executive Vice President and Chief Medical Officer, would separate from Imunon effective as of February 28, 2023.

Departed

Robert W. Hooper

Director

IMNN · Imunon, Inc.

Effective: 2022-12-31
Filed: January 3, 2023, 6:59 PM ET

On December 31, 2022, Robert W. Hooper, a Class II member of the Board of Directors (the “Board”) of Imunon, Inc. (the “Registrant”), announced that he has decided to retire from the Registrant’s Board effective December 31, 2022.

Earnings & guidance

2026-Q1 EPS reported -$0.84 vs consensus -$1.13 ▲ beat (+25.8%) filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

13 positive 8 negative 29 neutral

source · IMNN on sec.gov